Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b Single Arm, Open-label Trial of RYZ101 in Combination With Carboplatin + Etoposide + Atezolizumab in Subjects With Somatostatin Receptor Expressing (SSTR+) Extensive Stage Small Cell Lung Cancer (ES-SCLC)

NCT05595460 is registered in ClinicalTrials.gov with RayzeBio, Inc. as lead sponsor.

NCT NCT05595460
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05595460 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b Single Arm, Open-label Trial of RYZ101 in Combination With Carboplatin + Etoposide + Atezolizumab in Subjects With Somatostatin Receptor Expressing (SSTR+) Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Lead sponsor
RayzeBio, Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
October 10, 2022
Completion date
July 31, 2027
Enrollment
21 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

sclc,extensive stage